ArticleAnnals of hematology2026
Adiponectin levels during steady state and vaso-occlusive crisis in Nigerian children with sickle cell anaemia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell anaemia (SCA) is a chronic inflammatory hemoglobinopathy marked by recurrent vaso-occlusive crises (VOC) and end-organ damage. Adiponectin, an adipokine with anti-inflammatory and insulin-sensitizing properties, is well-studied in metabolic disorders but remains underexplored in SCA. This study assessed serum adiponectin levels in Nigerian children with SCA during steady state and VOC. We conducted a cross-sectional study involving 50 children with homozygous sickle cell genotype (HbSS) and 46 age- and sex-matched healthy controls with normal adult haemoglobin genotype (HbAA). Adiponectin levels were measured using ELISA, and group comparisons were performed. Multivariable linear regression was used to assess associations between adiponectin and clinical variables. Children with SCA had significantly higher adiponectin levels (median 3.2 µg/mL, IQR 2.20–4.38) compared to healthy controls (0.4 µg/mL, IQR 0.3–0.6; p<0.0001). Among the SCA group, those in VOC had higher adiponectin concentrations than those in steady state (median 4.00 µg/mL vs. 2.15 µg/mL; p<0.0001). These differences remained significant after adjusting for age, sex, BMI, and socio-economic status (p<0.001). Adiponectin levels are elevated in children with SCA, particularly during VOC, suggesting its potential role as a dynamic biomarker of disease activity. These findings contribute to understanding the inflammatory profile of paediatric SCA and support further research into adiponectin as a non-invasive marker in clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.